#99 Bleeding vs. Clotting Risk: Gray Matters Segment
Core IM | Internal Medicine Podcast
Is a Doe Act the Right Choice?
Even in the clinical trials of the pixaban versus low molecular weight heparin for cancer associated thrombosis 6% of the patients on a pixaban had a recurrent clot in the first six months while they were still on the drug. So it's not such a rare thing that a cancer patients clot worsens while on anticoagulation. Going forward I think I'll have to remember to consider clot formation in patients onAnticoagulation especially if it's a patient who might have cancer.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
